Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03912818
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:35.469175+00:00
Published At
2023-09-11T00:00:00+00:00
Record Updated At
2023-09-11
Results Posted At
2023-09-11
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Bladder Adenocarcinoma", "Bladder Mixed Adenocarcinoma", "Bladder Squamous Cell Carcinoma", "Bladder Urothelial Carcinoma", "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant", "Infiltrating Bladder Urothelial Carcinoma With Giant Cells", "Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation", "Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation", "Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant", "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant", "Infiltrating Bladder Urothelial Carcinoma, Nested Variant", "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-09-11"
protocolSection.identificationModule.nctId
"NCT03912818"
protocolSection.identificationModule.officialTitle
"Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-09-11"

Study condition terms

  • Bladder Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Bladder Mixed Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Bladder Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Bladder Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant (protocolSection.conditionsModule.conditions)
  • Infiltrating Bladder Urothelial Carcinoma With Giant Cells (protocolSection.conditionsModule.conditions)
  • Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation (protocolSection.conditionsModule.conditions)
  • Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation (protocolSection.conditionsModule.conditions)
  • Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant (protocolSection.conditionsModule.conditions)
  • Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant (protocolSection.conditionsModule.conditions)
  • Infiltrating Bladder Urothelial Carcinoma, Nested Variant (protocolSection.conditionsModule.conditions)
  • Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.